Market Summary
USD173.85-1.67
Market Closed-0.95%
ALNY Stock Price
ALNY RSI Chart
ALNY Valuation
ALNY Price/Sales (Trailing)
ALNY Profitability
ALNY Fundamentals
ALNY Revenue
ALNY Earnings
Price Action
52 Week Range
171.08242.97
(Low)(High)
Last 7 days
-17%
Last 30 days
-7.0%
Last 90 days
-11.8%
Trailing 12 Months
-17.2%
ALNY Financial Health
ALNY Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ALNY
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-07 | Garg Pushkal | sold | -766,083 | 183 | -4,166 | cmo & evp dev & med affairs |
2023-08-04 | Vaishnaw Akshay | sold | -753,986 | 185 | -4,057 | president |
2023-08-04 | Greenstreet Yvonne | sold | -753,986 | 185 | -4,057 | chief executive officer |
2023-08-04 | Poulton Jeffrey V. | sold | -643,037 | 185 | -3,460 | evp, chief financial officer |
2023-08-04 | Garg Pushkal | sold | -643,223 | 185 | -3,461 | cmo & evp dev & med affairs |
2023-08-03 | Poulton Jeffrey V. | acquired | - | - | 7,627 | evp, chief financial officer |
2023-08-03 | Vaishnaw Akshay | acquired | - | - | 8,941 | president |
2023-08-03 | BONNEY MICHAEL W | sold | -1,195,310 | 185 | -6,448 | - |
2023-08-03 | Greenstreet Yvonne | acquired | - | - | 8,941 | chief executive officer |
2023-08-03 | Garg Pushkal | acquired | - | - | 7,627 | cmo & evp dev & med affairs |
Which funds bought or sold ALNY recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | added | 31.25 | 784 | 3,989 | -% |
2023-08-29 | EFG Asset Management (Americas) Corp. | added | 3.66 | -51,951 | 2,988,710 | 0.69% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | -64.00 | 946 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -30,102 | 550,826 | -% |
2023-08-21 | BOKF, NA | reduced | -2.88 | -81,914 | 952,739 | 0.02% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.29 | -2,995,740 | 37,721,700 | 0.05% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 7.57 | 17,343 | 771,759 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -16.59 | -2,617,000 | 9,894,000 | 0.10% |
2023-08-18 | Humankind Investments LLC | new | - | 211,403 | 211,403 | 0.08% |
2023-08-17 | Orion Portfolio Solutions, LLC | reduced | -5.15 | -50,096 | 447,499 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Alnylam Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 3.3% | 4,074,144 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 13.5% | 16,593,958 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.35% | 11,507,116 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 5.09% | 6,261,642 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.0% | 8,665,702 | SC 13G/A | |
| Jan 19, 2023 | baillie gifford & co | 7.65% | 9,407,871 | SC 13G/A | |
| Sep 09, 2022 | capital world investors | 10.7% | 12,816,777 | SC 13G | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 5.4% | 6,535,368 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 8.95% | 10,702,771 | SC 13G/A |
Recent SEC filings of Alnylam Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 04, 2023 | 4 | Insider Trading | |
| Aug 03, 2023 | 8-K | Current Report | |
| Aug 03, 2023 | 10-Q | Quarterly Report | |
| Jul 26, 2023 | 8-K | Current Report | |
| Jun 30, 2023 | 8-K | Current Report |
Peers (Alternatives to Alnylam Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.18 | 4.26 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 28.7M | - | 1.35% | 3552.08% | -0.62 | - | - | -31.51% |
Alnylam Pharmaceuticals News
Returns for ALNY
Cumulative Returns on ALNY
11.9%
10-Year Cumulative Returns
12.3%
7-Year Cumulative Returns
13.2%
5-Year Cumulative Returns
9.9%
3-Year Cumulative Returns
Risks for ALNY
What is the probability of a big loss on ALNY?
100%
Probability that Alnylam Pharmaceuticals stock will be more than 20% underwater in next one year
36.9%
Probability that Alnylam Pharmaceuticals stock will be more than 30% underwater in next one year.
17.7%
Probability that Alnylam Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ALNY drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Alnylam Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Alnylam Pharmaceuticals
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 8.2% | 1,237,385,000 | 1,143,449,000 | 1,037,418,000 | 960,918,000 | 884,245,000 | 879,980,000 | 844,287,000 | 749,314,000 | 687,534,000 | 570,943,000 | 492,853,000 | 400,972,000 | 345,180,000 | 285,932,000 | 219,750,000 | 169,102,000 | 153,655,467 | 138,208,933 | 122,762,400 | 107,315,867 | 91,869,333 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 719,688,000 |
| S&GA Expenses | 5.6% | 844,551,000 | 799,846,000 | 770,658,000 | 746,696,000 | 652,912,000 | 628,251,000 | 620,639,000 | 600,548,000 | 625,945,000 | 608,518,000 | 588,420,000 | 578,406,000 | 531,285,000 | 516,158,000 | 479,005,000 | 431,416,000 | 427,610,000 | 399,520,000 | 382,359,000 | 341,126,000 | 272,225,000 |
| R&D Expenses | 4.5% | 986,505,000 | 943,691,000 | 883,015,000 | 850,026,000 | 799,227,000 | 776,150,000 | 792,156,000 | 731,575,000 | 698,786,000 | 671,147,000 | 654,819,000 | 687,651,000 | 686,664,000 | 695,558,000 | 655,114,000 | 584,849,000 | 563,998,000 | 537,690,000 | 505,420,000 | 492,156,000 | 447,463,000 |
| EBITDA | 100.0% | - | -868,365,000 | -926,557,000 | -975,871,000 | -773,788,000 | -694,931,000 | -661,556,000 | -654,141,000 | -717,113,000 | -716,458,000 | -736,332,000 | -802,777,000 | -792,519,000 | -873,101,000 | -868,078,000 | - | - | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.76 | -0.89 | -1.02 | -0.88 | -0.79 | -0.78 | -0.87 | -1.04 | -1.25 | -1.49 | -2.00 | -2.30 | -3.05 | -3.95 | - | - | - | - | - | - |
| Interest Expenses | -8.8% | 129,987,000 | 142,561,000 | 155,968,000 | 162,871,000 | 162,061,000 | 152,868,000 | 143,021,000 | 134,722,000 | 123,179,000 | 117,011,000 | 84,496,000 | 55,979,000 | 27,248,000 | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | 0.0% | -1,059,535,000 | -1,059,999,000 | -1,126,993,000 | -1,180,274,000 | -978,567,000 | -892,225,000 | -852,144,000 | -835,441,000 | -883,657,000 | -873,229,000 | -855,600,000 | -888,584,000 | -845,061,000 | -885,679,000 | -885,253,000 | -819,750,000 | -855,658,000 | -800,618,000 | -760,674,000 | -691,821,000 | -569,921,000 |
| EBT Margin | 100.0% | - | -0.93 | -1.09 | -1.23 | -1.11 | -1.01 | -1.01 | -1.11 | -1.29 | -1.53 | -1.74 | -2.22 | -2.45 | -3.10 | -4.03 | - | - | - | - | - | - |
| Net Income | 0.1% | -1,063,538,000 | -1,064,916,000 | -1,131,156,000 | -1,182,123,000 | -980,717,000 | -892,874,000 | -852,824,000 | -837,904,000 | -886,681,000 | -876,351,000 | -858,281,000 | -890,926,000 | -846,170,000 | -886,422,000 | -886,116,000 | -821,372,000 | -858,119,000 | -802,198,000 | -761,497,000 | -692,283,000 | -569,938,000 |
| Net Income Margin | 100.0% | - | -0.93 | -1.09 | -1.23 | -1.11 | -1.01 | -1.01 | -1.12 | -1.29 | -1.53 | -1.74 | -2.22 | -2.45 | -3.10 | -4.03 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -604,647,000 | -613,333,000 | -631,747,000 | -660,051,000 | -654,279,000 | -718,065,000 | -690,850,000 | -653,496,000 | -672,382,000 | -685,322,000 | -775,295,000 | -871,241,000 | -451,802,000 | -418,583,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 0.3% | 3,402 | 3,392 | 3,546 | 3,535 | 3,330 | 3,434 | 3,643 | 3,472 | 3,509 | 3,255 | 3,407 | 3,307 | 3,374 | 2,280 | 2,395 | 2,542 | 2,716 | 2,014 | 1,575 | 1,676 | 1,789 |
| Current Assets | -0.7% | 2,524 | 2,541 | 2,692 | 2,691 | 2,472 | 2,590 | 2,809 | 2,675 | 2,725 | 2,470 | 2,615 | 2,555 | 2,160 | 1,585 | 1,716 | 1,897 | 2,064 | 1,392 | 1,201 | 1,342 | 1,503 |
| Cash Equivalents | -2.1% | 658 | 672 | 866 | 1,073 | 576 | 534 | 822 | 1,094 | 746 | 380 | 497 | 497 | 581 | 468 | 547 | 923 | 1,136 | 725 | 420 | 317 | 361 |
| Inventory | -23.8% | 100 | 132 | 129 | 115 | 89.00 | 79.00 | 86.00 | 98.00 | 84.00 | 74.00 | 75.00 | 67.00 | 77.00 | 68.00 | 56.00 | 55.00 | 41.00 | 32.00 | 24.00 | 11.00 | - |
| Net PPE | 0.8% | 527 | 523 | 523 | 515 | 508 | 504 | 502 | 485 | 471 | 465 | 465 | 445 | 439 | 430 | 425 | 396 | 372 | 342 | 321 | 273 | 228 |
| Liabilities | 4.4% | 3,811 | 3,651 | 3,705 | 3,603 | 3,154 | 3,032 | 3,055 | 2,716 | 2,656 | 2,329 | 2,391 | 2,092 | 1,975 | 930 | 956 | 935 | 959 | 467 | 273 | 198 | 169 |
| Current Liabilities | 17.1% | 789 | 673 | 768 | 773 | 658 | 606 | 696 | 611 | 555 | 495 | 585 | 480 | 384 | 339 | 353 | 353 | 329 | 149 | 179 | 122 | 114 |
| Long Term Debt | - | - | - | - | - | 678 | 677 | 676 | 434 | 433 | 192 | 191 | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -57.4% | -408 | -259 | -158 | - | 176 | 401 | 588 | 756 | 853 | 926 | 1,016 | 1,215 | 1,400 | 1,350 | 1,439 | 1,607 | 1,757 | 1,547 | 1,302 | 1,478 | 1,621 |
| Retained Earnings | -4.1% | -7,019 | -6,743 | -6,569 | -6,361 | -5,955 | -5,678 | -5,438 | -5,179 | -4,975 | -4,785 | -4,585 | -4,341 | -4,088 | -3,909 | -3,727 | -3,450 | -3,242 | -3,022 | -2,840 | -2,629 | -2,384 |
| Additional Paid-In Capital | 1.9% | 6,647 | 6,522 | 6,455 | 6,337 | 6,173 | 6,117 | 6,058 | 5,969 | 5,863 | 5,747 | 5,644 | 5,593 | 5,520 | 5,290 | 5,201 | 5,091 | 5,034 | 4,602 | 4,175 | 4,140 | 4,038 |
| Shares Outstanding | 0.5% | 125 | 124 | 124 | 123 | 121 | 120 | 120 | 119 | 118 | 117 | 116 | 116 | 115 | 113 | 112 | 109 | 109 | 105 | 101 | 101 | 101 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 11.9% | -472 | -536 | -541 | -559 | -578 | -577 | -641 | -614 | -590 | -604 | -614 | -687 | -760 | -336 | -278 | -232 | -204 | -595 | -562 | -515 | -459 |
| Share Based Compensation | 18.8% | 287 | 241 | 231 | 232 | 138 | 139 | 166 | 155 | 159 | 161 | 140 | 172 | 181 | 177 | 175 | 137 | 179 | 170 | 158 | 157 | 95.00 |
| Cashflow From Investing | -63.0% | 89.00 | 241 | 169 | -104 | -506 | -492 | -273 | 42.00 | 120 | -477 | -435 | -558 | -558 | -406 | -417 | 52.00 | 158 | 510 | 273 | -136 | -369 |
| Cashflow From Financing | 5.3% | 460 | 437 | 426 | 655 | 931 | 1,231 | 1,247 | 1,173 | 633 | 992 | 995 | 817 | 763 | 486 | 823 | 788 | 822 | 415 | 65.00 | 767 | 783 |
ALNY Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 318,754 | $ 224,818 | $ 638,044 | $ 438,077 |
| Operating costs and expenses: | ||||
| Cost of goods sold | 75,336 | 34,038 | 116,768 | 57,495 |
| Cost of collaborations and royalties | 10,034 | 6,770 | 23,471 | 18,940 |
| Research and development | 248,526 | 205,712 | 479,095 | 375,605 |
| Selling, general and administrative | 214,689 | 169,984 | 398,348 | 324,455 |
| Total operating costs and expenses | 548,585 | 416,504 | 1,017,682 | 776,495 |
| Loss from operations | (229,831) | (191,686) | (379,638) | (338,418) |
| Other (expense) income: | ||||
| Interest expense | (30,035) | (42,609) | (58,990) | (84,971) |
| Interest income | 21,075 | 1,899 | 39,730 | 2,911 |
| Other expense, net | (35,418) | (42,277) | (47,673) | (93,551) |
| Total other expense, net | (44,378) | (82,987) | (66,933) | (175,611) |
| Loss before income taxes | (274,209) | (274,673) | (446,571) | (514,029) |
| Provision for income taxes | (1,815) | (2,729) | (3,554) | (3,714) |
| Net loss | $ (276,024) | $ (277,402) | $ (450,125) | $ (517,743) |
| Net loss per common share - basic (in dollars per share) | $ (2.21) | $ (2.29) | $ (3.62) | $ (4.29) |
| Net loss per common share - diluted (in dollars per share) | $ (2.21) | $ (2.29) | $ (3.62) | $ (4.29) |
| Weighted-average common shares used to compute basic net loss per common share (in shares) | 124,659 | 120,896 | 124,387 | 120,646 |
| Weighted-average common shares used to compute diluted net loss per common share (in shares) | 124,659 | 120,896 | 124,387 | 120,646 |
| Statements of Comprehensive Loss | ||||
| Net loss | $ (276,024) | $ (277,402) | $ (450,125) | $ (517,743) |
| Other comprehensive income (loss): | ||||
| Unrealized (loss) gain on marketable securities | (2,025) | (1,734) | 2,100 | (8,951) |
| Foreign currency translation gain (loss) | 4,073 | (2,459) | 5,483 | (83) |
| Defined benefit pension plans, net of tax | (4) | 34 | (9) | 69 |
| Total other comprehensive income (loss) | 2,044 | (4,159) | 7,574 | (8,965) |
| Comprehensive loss | (273,980) | (281,561) | (442,551) | (526,708) |
| Net product revenues | ||||
| Revenues: | ||||
| Total revenues | 305,705 | 213,515 | 582,033 | 400,387 |
| Net revenues from collaborations | ||||
| Revenues: | ||||
| Total revenues | 5,844 | 9,025 | 42,306 | 34,970 |
| Royalty revenue | ||||
| Revenues: | ||||
| Total revenues | $ 7,205 | $ 2,278 | $ 13,705 | $ 2,720 |
ALNY Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 657,800 | $ 866,394 |
| Marketable debt securities | 1,372,451 | 1,297,890 |
| Marketable equity securities | 27,256 | 28,122 |
| Accounts receivable, net | 220,635 | 237,963 |
| Inventory | 100,453 | 128,962 |
| Prepaid expenses and other current assets | 145,452 | 132,916 |
| Total current assets | 2,524,047 | 2,692,247 |
| Property, plant and equipment, net | 527,474 | 523,494 |
| Operating lease right-of-use assets | 208,801 | 215,136 |
| Restricted investments | 49,388 | 49,390 |
| Other assets | 92,686 | 66,092 |
| Total assets | 3,402,396 | 3,546,359 |
| Current liabilities: | ||
| Accounts payable | 59,746 | 98,094 |
| Accrued expenses | 598,530 | 545,460 |
| Operating lease liability | 42,074 | 41,967 |
| Deferred revenue | 54,639 | 42,105 |
| Liability related to the sale of future royalties | 33,650 | 40,289 |
| Total current liabilities | 788,639 | 767,915 |
| Operating lease liability, net of current portion | 253,416 | 261,339 |
| Deferred revenue, net of current portion | 194,129 | 193,791 |
| Convertible debt | 1,018,843 | 1,016,942 |
| Liability related to the sale of future royalties, net of current portion | 1,298,446 | 1,252,015 |
| Other liabilities | 257,054 | 212,580 |
| Total liabilities | 3,810,527 | 3,704,582 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.01 par value per share, 250,000 shares authorized; 124,901 shares issued and outstanding as of June 30, 2023; 123,925 shares issued and outstanding as of December 31, 2022 | 1,250 | 1,240 |
| Additional paid-in capital | 6,647,173 | 6,454,540 |
| Accumulated other comprehensive loss | (37,080) | (44,654) |
| Accumulated deficit | (7,019,474) | (6,569,349) |
| Total stockholders’ deficit | (408,131) | (158,223) |
| Total liabilities and stockholders’ deficit | $ 3,402,396 | $ 3,546,359 |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.